These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 35255180)
1. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma. Qi W; Bai Y; Wang Y; Liu L; Zhang Y; Yu Y; Chen H APMIS; 2022 Jul; 130(7):371-382. PubMed ID: 35255180 [TBL] [Abstract][Full Text] [Related]
2. Integrated Single-cell and Transcriptome Sequencing Analyses Identified PREX1 as an Immune-related Prognostic Biomarker for Liver Hepatocellular Carcinoma. Yang J; Fan LY; Shi KY Int J Med Sci; 2024; 21(8):1559-1574. PubMed ID: 38903921 [No Abstract] [Full Text] [Related]
3. Analysis of the implication of steroid 5 alpha-reductase 3 on prognosis and immune microenvironment in Liver Hepatocellular Carcinoma. Lu Y; Liu Z; Zheng Y; Liu X; Liu X; Chen N; Mao K; Lin W Ann Med; 2024 Dec; 56(1):2408463. PubMed ID: 39340288 [TBL] [Abstract][Full Text] [Related]
4. RAC1 serves as a prognostic factor and correlated with immune infiltration in liver hepatocellular carcinoma. Li Y; Gu A; Yang L; Wang Q J Cancer Res Clin Oncol; 2024 Sep; 150(9):418. PubMed ID: 39264423 [TBL] [Abstract][Full Text] [Related]
5. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq. Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X Front Immunol; 2024; 15():1397541. PubMed ID: 38774870 [TBL] [Abstract][Full Text] [Related]
6. Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma. Pan Y; Zhu Q; Hong T; Cheng J; Tang X Aging (Albany NY); 2024 May; 16(10):9047-9071. PubMed ID: 38787389 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of N Zhu HX; Lu WJ; Zhu WP; Yu S J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346 [TBL] [Abstract][Full Text] [Related]
8. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma. Jin W; Wang G; Dong M; Wang X Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503 [TBL] [Abstract][Full Text] [Related]
9. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma. Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618 [TBL] [Abstract][Full Text] [Related]
10. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma. Ding D; Wang D; Qin Y Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299 [TBL] [Abstract][Full Text] [Related]
11. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma. Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368 [TBL] [Abstract][Full Text] [Related]
12. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma. Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215 [TBL] [Abstract][Full Text] [Related]
13. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors. Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370 [TBL] [Abstract][Full Text] [Related]
14. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma. Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186 [No Abstract] [Full Text] [Related]
15. Type-1 Na Zhou YT; Chen H; Ai M; Li SS; Li BY; Zhao Y; Cai WW; Hou B; Ni LL; Xu F; Qiu LY Life Sci; 2021 Aug; 278():119613. PubMed ID: 34000263 [TBL] [Abstract][Full Text] [Related]
16. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine Kinase 1 in pan-cancer and identification in hepatocellular carcinoma. Chen D; Zhou W; Chen J; Wang J Aging (Albany NY); 2023 Dec; 15(24):15504-15524. PubMed ID: 38157278 [TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma. Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221 [TBL] [Abstract][Full Text] [Related]
18. KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma. Qiu MJ; Zhang L; Chen YB; Zhu LS; Zhang B; Li QT; Yang SL; Xiong ZF Int J Biochem Cell Biol; 2021 Aug; 137():106037. PubMed ID: 34217812 [TBL] [Abstract][Full Text] [Related]
19. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target. Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L Front Immunol; 2023; 14():1158360. PubMed ID: 37483608 [TBL] [Abstract][Full Text] [Related]
20. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma. Wang J; Huang Z; Lu H; Zhang R; Feng Q; He A Comput Math Methods Med; 2022; 2022():1258480. PubMed ID: 35242200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]